Malaria is caused by a parasite carried by a mosquito. Currently, there is no vaccine
licensed to prevent malaria. The purpose of this study is to find the most effective and
safest dose of an experimental vaccine for the treatment of malaria. Participants will
include 72 healthy adults, ages18 to 45, enrolled at Vanderbilt University Medical Center and
Stanford University. Volunteers will receive 3 doses of either the malaria vaccine or placebo
(contains no vaccine) by injection into a muscle at 0, 1 and 6 months. Investigators will
evaluate how the body responds to increasing dosage strengths of the vaccine. Study
procedures include physical exam, multiple blood draws, and completion of a memory aid
(diary). Each participant will be actively involved in the study for about 12 months. Then,
an annual phone call will be made to check for any serious illness events for a period of 5
years.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)